Filana Therapeutics (FLNA) Retained Earnings (2010 - 2026)

Filana Therapeutics has reported Retained Earnings for 17 years, with the latest figure at $578.6 million in Q2 2026.

• On a quarterly basis, Retained Earnings rose 3.2% year-over-year to $578.6 million in Q2 2026; TTM through Jun 2026 was $578.6 million, a 3.2% increase from a year earlier, with the FY2025 full-year figure at $570.4 million, up 3.57% from the prior year.
• Retained Earnings was $578.6 million for Q2 2026 at Filana Therapeutics, up from $574.5 million in the prior quarter.
• The five-year high for Retained Earnings was $578.6 million in Q2 2026, with the low at $434.3 million in Q1 2024.
• Average Retained Earnings over 5 years is $523.9 million, with a median of $528.3 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings fell 15.14% in 2024, then grew 28.05% in 2025.
• Over 5 years, Retained Earnings stood at $511.0 million in 2022, then rose by 1.4% to $518.2 million in 2023, then gained by 6.29% to $550.8 million in 2024, then climbed by 3.57% to $570.4 million in 2025, then gained by 1.43% to $578.6 million in 2026.
• The last three Retained Earnings figures came in at $578.6 million (Q2 2026), $574.5 million (Q1 2026), and $570.4 million (Q4 2025), per Business Quant data.